期刊档案 · 医学-药学

Contemporary Clinical Trials

ISSN 1551-7144 · eISSN 1559-2030 · Elsevier Inc. · UNITED STATES · Bimonthly · 创刊 2005

Contemporary Clinical Trials 中科院 医学 3区(2025 年升级版),影响因子 1.87,混合开放获取,APC 约 3,140 美元,近 24 个月 112 篇文章投稿到接收中位 164 天,录用比例容易(社区反馈),2025 年发文 311 篇,SCIE、Scopus 收录。

影响因子1.87LetPub 汇总的最新公布值
中科院分区医学 3区2025 年升级版大类 · 2026 新锐版 医学 4区
审稿周期164 天投稿到接收中位数 · 近 24 个月 112 篇文章 · PubMed
版面费3,140 USD混合期刊,仅开放获取发表时收取
录用比例容易投稿社区平均反馈
年发文量311 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Contemporary Clinical Trials 由 Elsevier Inc. 出版,属中科院医学大类(2025 升级版3区)。按 OpenAlex 近年发文统计,该刊主要发表 Statistical Methods in Clinical Trials、Ethics in Clinical Research、Health Systems, Economic Evaluations, Quality of Life 等主题的论文,这 3 个主题约占 23.9%。(根据 OpenAlex 主题统计与中科院分区数据生成)

Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers not exceeding 4,000 words, short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.The following topics are covered in the journal:Unconventional design features of specific trials and their rationalePreliminary or full results of clinical trials with unconventional design featuresStatistical methods for all aspects of clinical trialsMethodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessmentData management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registriesRegulatory requirements and their impact on clinical trialsEthical and legal considerations in clinical trialsRisk-benefit, cost-effectiveness and decision analyses in clinical trialsContemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment.Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients.Authors are also welcome to submit to the journal's open access companion title, Contemporary Clinical Trials Communications.

摘自期刊官网 Aims & Scope

研究方向(LetPub):医学-药学

主编 Howard Sesso出版商官网

编委会国家分布:中国大陆 2 位(约 1%);主要国家 美国 206、加拿大 13、意大利 10、英国 7、澳大利亚 4(共 272 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Statistical Methods in Clinical TrialsMathematics11%
  2. Ethics in Clinical ResearchMedicine7.3%
  3. Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance5.7%
  4. Obesity, Physical Activity, DietMedicine5.4%
  5. Mobile Health and mHealth ApplicationsHealth Professions5.2%
  6. Human auditory perception and evaluationEngineering4.8%
  7. Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.8%
  8. Meta-analysis and systematic reviewsDecision Sciences4.7%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 3 区
类别学科分区
大类医学3 区
小类医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL3 区
小类药学PHARMACOLOGY & PHARMACY3 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 4 区
类别学科分区
大类医学4 区
小类医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL3 区
小类药学PHARMACOLOGY & PHARMACY3 区

Top 期刊:否综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)医学 3 区
类别学科分区
大类医学3 区
小类医学:研究与实验MEDICINE, RESEARCH & EXPERIMENTAL3 区
小类药学PHARMACOLOGY & PHARMACY3 区

Top 期刊:否综述期刊:否

数据库收录

SCIEScopusLetPub

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子
1.87LetPub ·
影响因子(出版商公布)
1.9出版商官网 ·
CiteScore 2026-06
3.6LetPub ·
CiteScore(出版商公布)
3.6出版商官网 ·
SJR 2026-06
0.97LetPub ·
SNIP 2026-06
0.83LetPub ·
h-index
51LetPub ·
h-index
94OpenAlex ·
i10-index
1,934OpenAlex ·
两年平均被引
1.8OpenAlex ·
自引率
5.3%LetPub ·
Gold OA 文章占比
25.66%LetPub ·

发文规模

年文章数
289LetPub ·

逐年发文量 OpenAlex 统计 · 累计 4,081 篇 · 当年数据不完整

年份发文量其中 OA被引
202620913527
2025311206378
20242722151,021
20232621961,590
20223112153,058
20213102023,983

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 PubMed 登记的稿件日期 · 至

164 天投稿到接收中位数 · P25–P75 128 天 – 211 天

接收到上线
中位数 2 天(112 篇)
投稿到上线
中位数 169 天
样本
112 篇有投稿与接收日期的文章(窗口内共 598 篇),最近一篇接收于

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

其他来源

平均审稿速度(社区反馈)
一般,3-8周来源Elsevier官网:平均5.5周LetPub ·
平均录用比例(社区反馈)
容易LetPub ·
投稿到首次决定
10 天出版商官网 ·
外审后首次决定
93 天出版商官网 ·
投稿到接收
142 天出版商官网 ·
接收到发表
2 天出版商官网 ·
评审方式
单盲同行评审出版商官网

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

混合开放获取LetPub

订阅期刊,作者可付费选择开放获取发表。

来源文章处理费费用减免许可证观测时间
OpenAlexUSD 3,140 / EUR 2,940 / GBP 2,510 / JPY 389,450——
出版商官网USD 3,410——

混合期刊的文章处理费仅在作者选择开放获取发表时收取;按订阅方式发表通常不收费。

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

接收的文章类型4 种,含篇幅限制
  1. full length articlesBeside Full Length Articles (limited to 4,000 or fewer words), Contemporary Clinical Trials invites Short Communications (manuscripts of 1500 or fewer words) an…未说明篇幅
  2. letters to the editorBeside Full Length Articles (limited to 4,000 or fewer words), Contemporary Clinical Trials invites Short Communications (manuscripts of 1500 or fewer words) an…未说明篇幅
  3. short communicationBeside Full Length Articles (limited to 4,000 or fewer words), Contemporary Clinical Trials invites Short Communications (manuscripts of 1500 or fewer words) an…正文 ≤ 1,500 词
  4. short communicationsBeside Full Length Articles (limited to 4,000 or fewer words), Contemporary Clinical Trials invites Short Communications (manuscripts of 1500 or fewer words) an…未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
AI 使用 Declaration of generative AI use

Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…

原文 ↗出版商官网 ·
作者资格 Group authorship

Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…

原文 ↗出版商官网 ·
利益冲突 Declaration of competing interests

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …

原文 ↗出版商官网 ·
许可与版权 License options

Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.

原文 ↗出版商官网 ·
开放获取 Open access

We refer you to our open access information page to learn about open access options for this journal.

原文 ↗出版商官网 ·
同行评审 Peer review

Single anonymized review process 模型摘要

This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…

原文 ↗出版商官网 ·
预印本 Preprints

Preprint sharing allowed 模型摘要

Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Elsevier Inc.
出版国家或地区
UNITED STATES
出版语言
English
出版周期
Bimonthly
创刊年份
2005
ISSN
1551-7144
电子版 ISSN
1559-2030
官方链接

常见问题

关于 Contemporary Clinical Trials 的常见问题

Contemporary Clinical Trials 是中科院几区期刊?

2025 年升级版分区表中,Contemporary Clinical Trials 为医学 3区,小类 医学:研究与实验 / 药学 3 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。

Contemporary Clinical Trials 的影响因子是多少?

LetPub 汇总的最新公布影响因子为 1.87,CiteScore 为 3.6,h-index 为 94。

Contemporary Clinical Trials 的审稿周期多长?

按 2024年10月至2026年10月(近 24 个月)112 篇已发表文章登记的日期,投稿到接收的中位数为 164 天(四分位 128–211 天);投稿社区反馈的平均审稿速度为3–8 周,平均录用比例反馈为“容易”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Contemporary Clinical Trials 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 272 位编委中,中国大陆 2 位(约 1%);人数最多的国家是 美国(206 位)、加拿大(13 位)、意大利(10 位)。统计按编委会页面列出的机构国家计,仅供参考。

Contemporary Clinical Trials 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,Contemporary Clinical Trials 被 SCIE、Scopus 收录。

Contemporary Clinical Trials 是开放获取期刊吗?版面费多少?

Contemporary Clinical Trials 为混合开放获取。选择开放获取发表时APC 约 3,140 美元。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。